Morges, Switzerland - Leman Cardiovascular SA the developer of the Kalangos biological heart valve announces that clinical trials in humans will start in Europe in the first quarter of 2010. This is a landmark on the way to achieving CE marking for this new design. Pre-clinical study results have shown superior performance characteristics. |
